The more I read about Origin Therapeutics the more excited I am for them to go public. Through a portfolio including both private and public companies, it’s going to give retail investors a great opportunity to gain exposure to companies in the psychedelic field that would normally only be accessible to venture capitalists. Providing access to the largest growth potential in the industry.
Their portfolio is quite diverse, ranging from businesses involved in the promotion of psychedelics, to clinics and manufacturers. They also offer 0% fees unlike a lot of funds, especially in the psychedelics industry.
Origin is expected to IPO on the CSE under $ORIG.C. I’m looking for further updates on IPO to be made once the psychedelics market starts to show signs of a swing from current lows. This should provide Origin with the largest opportunity to capitalize on more investor interest in the industry as a whole.
With Horizons Psychadelics ETF $HPSYF showing some strong gains of 25% off of a bounce from all-time lows, I’m expecting to see some stabilization and correction in the industry throughout the first two quarters of this year. Hopefully, public acceptance of the industry and further easing of regulations will correlate to provide the perfect environment for psychedelics to reach previous market levels, offering insane growth potential from current prices.
I recommend checking out Origin’s investor presentation to get a better idea about its operations and what the company has to offer.
https://originpsychedelics.com/wp-content/uploads/2021/11/Origin-Presentation-V28.pdf